Skip to main
  1. Stocks
  2. Moderna
  3. Forecast
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 7%
Buy 7%
Hold 53%
Sell 20%
Strong Sell 13%

Bulls say

Moderna is supported by a growing commercial base, with 3Q:26 product sales of $1.27 billion and raised 2026 revenue guidance to 15-25% growth, while its $8 billion cash balance and $3.19 billion in long-term debt suggest ample financial flexibility. Its outlook is further strengthened by the Phase III INTerpath-001 results, where intismeran plus KEYTRUDA improved recurrence-free survival by 42% and distant metastasis-free survival by 38%, supporting a 2027 adjuvant melanoma approval and potential expansion into other cancers. Beyond oncology, Moderna’s 25 clinical mRNA candidates across infectious disease, cardiovascular disease, and rare genetic disease, plus approved COVID and flu vaccines, provide multiple shots of revenue diversification and long-term growth.

Bears say

Moderna is a commercial-stage biotech whose investment case is weakened by heavy dependence on mRNA programs that could fail in the clinic or never secure approval, despite having 25 candidates in clinical studies as of March 2026 across infectious disease, oncology, cardiovascular disease, and rare genetic diseases. The company’s sales may also fall short of forecasts while spending runs above budget, pressuring future profitability and making its broad pipeline less valuable if execution slips. In particular, the decision not to conduct a 3rd season of the Phase III NOVA-301 trial and instead seek FDA guidance on mRNA-1403 forced a $1.01 billion value reduction, underscoring meaningful development and regulatory uncertainty.

Moderna (MRNA) has been analyzed by 15 analysts, with a consensus rating of Hold. 7% of analysts recommend a Strong Buy, 7% recommend Buy, 53% suggest Holding, 20% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Moderna (MRNA) Analyst Forecast & Price Prediction

Get the latest Moderna (MRNA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Moderna (MRNA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 15 analysts, Moderna (MRNA) has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $112.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $112.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Moderna (MRNA) Analyst Forecast & Price Prediction

Get the latest Moderna (MRNA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Moderna (MRNA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MRNA stock data and trends